Your browser doesn't support javascript.
loading
High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.
Labbé, David P; Zadra, Giorgia; Yang, Meng; Reyes, Jaime M; Lin, Charles Y; Cacciatore, Stefano; Ebot, Ericka M; Creech, Amanda L; Giunchi, Francesca; Fiorentino, Michelangelo; Elfandy, Habiba; Syamala, Sudeepa; Karoly, Edward D; Alshalalfa, Mohammed; Erho, Nicholas; Ross, Ashley; Schaeffer, Edward M; Gibb, Ewan A; Takhar, Mandeep; Den, Robert B; Lehrer, Jonathan; Karnes, R Jeffrey; Freedland, Stephen J; Davicioni, Elai; Spratt, Daniel E; Ellis, Leigh; Jaffe, Jacob D; DʼAmico, Anthony V; Kantoff, Philip W; Bradner, James E; Mucci, Lorelei A; Chavarro, Jorge E; Loda, Massimo; Brown, Myles.
Afiliação
  • Labbé DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Zadra G; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Yang M; Division of Urology, Department of Surgery, McGill University and Research Institute of the McGill University Health Centre, Montréal, QC, Canada.
  • Reyes JM; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lin CY; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Cacciatore S; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Ebot EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Creech AL; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Giunchi F; Cancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town, South Africa.
  • Fiorentino M; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Elfandy H; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Syamala S; Pathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, Bologna, IT, Italy.
  • Karoly ED; Pathology Service, Addarii Institute of Oncology, S-Orsola-Malpighi Hospital, Bologna, IT, Italy.
  • Alshalalfa M; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Erho N; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ross A; Metabolon, Morrisville, NC, USA.
  • Schaeffer EM; Decipher Biosciences, Vancouver, BC, Canada.
  • Gibb EA; Decipher Biosciences, Vancouver, BC, Canada.
  • Takhar M; James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Den RB; Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Lehrer J; Decipher Biosciences, Vancouver, BC, Canada.
  • Karnes RJ; Decipher Biosciences, Vancouver, BC, Canada.
  • Freedland SJ; Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
  • Davicioni E; Decipher Biosciences, Vancouver, BC, Canada.
  • Spratt DE; Department of Urology, Mayo Clinic Rochester, Rochester, MN, USA.
  • Ellis L; Department of Surgery, Division of Urology, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Jaffe JD; Surgery Section, Durham Veteran Affairs Medical Center, Durham, NC, USA.
  • DʼAmico AV; Decipher Biosciences, Vancouver, BC, Canada.
  • Kantoff PW; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
  • Bradner JE; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Mucci LA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Chavarro JE; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Loda M; The Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Brown M; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nat Commun ; 10(1): 4358, 2019 09 25.
Article em En | MEDLINE | ID: mdl-31554818
Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. Here, we demonstrate in a murine prostate cancer model, that high-fat diet (HFD) enhances the MYC transcriptional program through metabolic alterations that favour histone H4K20 hypomethylation at the promoter regions of MYC regulated genes, leading to increased cellular proliferation and tumour burden. Saturated fat intake (SFI) is also associated with an enhanced MYC transcriptional signature in prostate cancer patients. The SFI-induced MYC signature independently predicts prostate cancer progression and death. Finally, switching from a high-fat to a low-fat diet, attenuates the MYC transcriptional program in mice. Our findings suggest that in primary prostate cancer, dietary SFI contributes to tumour progression by mimicking MYC over expression, setting the stage for therapeutic approaches involving changes to the diet.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Regulação Neoplásica da Expressão Gênica / Proteínas Proto-Oncogênicas c-myc / Metaboloma / Dieta Hiperlipídica Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Animals / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Regulação Neoplásica da Expressão Gênica / Proteínas Proto-Oncogênicas c-myc / Metaboloma / Dieta Hiperlipídica Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Animals / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article